Observational studyThe Indian journal of medical research2025
Implication of microRNA-regulated PTEN expression in the clinico-pathology & survival outcomes in advanced ovarian cancer.
Observational study in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Phosphatase and TENs in homolog (PTEN), deleted on chromosome 10, plays a salient role in suppressing the proliferative phosphatidylinositol 3-kinase/protein kinase B(PI3K/AKT) signal in cancers. Growing evidence suggests that PTEN is downregulated by microRNAs (miRs) in aggressive cancers, which antagonise its tumour-suppressive activity. This study elucidates the effect of miR-214, miR-433, miR-100, and miR-152 on PTEN expression with important clinical parameters in individuals with Stage III-IV ovarian cancer (OC). Methods This prospective observational study enrolled 104 individuals with OC from January 2018 to December 2020. Demographic and clinical data were collected at presentation and follow up. Tissue samples were analysed using immunohistochemistry, Western blot, and quantitative real time PCR (qPCR)s. Statistical analyses included t-tests, chi-square, correlation coefficient, log-rank, Cox regression, and ROC analysis to assess clinical and survival outcomes. Results The included study participants with OC (mean age 49.29±9.68 yr) presented with advanced stages (96.6%) and had high-grade serous histological subtype (48.5%). Loss of PTEN expression was detected among 50.96 per cent, indicative of poor survival (HR>1; P=<0.05). MiR-214 (P=<0.001) and miR-433 (P=<0.001) were negatively associated, while miR-100 (P<0.001) and miR-152 (P=<0.001) were positively correlated with PTEN mRNA and protein, with miR-214, and miR-152 being independent risk factors to survival of OC patients (HR=>1). The sensitivity and specificity of PTEN and miRs range between 62.5-97 per cent, with diagnostic accuracy (P=<0.001). Interpretation & conclusions The degree of miR-214, miR-433, miR-100, and miR-152 exhibited dysregulation in OC (P=<0.001). The findings of this study suggest that miR-214 and miR-433 can downregulate PTEN whereas miR-100 and miR-152 may have a tumour suppressive role like PTEN. Thus, the signature miR network has the potential to become a diagnostic and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.